Enucleation offers a parenchyma-sparing surgical alternative for benign and low-grade pancreatic head tumors, with superior long-term quality of life compared to pancreatoduodenectomy.
Although enucleation results in higher rates of clinically relevant postoperative pancreatic fistula (CR-POPF), it is associated with fewer major complications, reduced delayed gastric emptying, and shorter hospitalization.
Patients undergoing enucleation experience lower incidence of new-onset diabetes and higher rates of return to work, particularly notable for tumors ≤2.5 cm in size.
Evidence supports enucleation as a technically feasible and oncologically acceptable approach for selected intraductal papillary mucinous neoplasms (IPMNs) and other low-risk pancreatic tumors in the head or uncinate process.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
